BACKGROUND: Adenoid cystic carcinomas (ACCs) are malignant salivary gland tumors noteworthy for high rates of late failure with limited salvage therapy options. We have previously shown increased Akt signaling is common in ACC and the human immunodeficiency virus (HIV) protease inhibitor nelfinavir (NFV) inhibits in vitro tumor growth by suppressing Akt signaling. This phase II trial was conducted to determine progression-free survival in response to NFV in patients with recurrent/endstage ACC who have failed standard therapies. METHODS: Eligible patients had recurrent or end-stage ACC and measureable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. NFV was provided at 1250 mg twice daily. RESULTS: Among 15 trial participants, median progression-free survival was 5.5 months (lower 95% bound 4.4 months). No patient achieved a RECIST partial or complete response to therapy. CONCLUSION: NFV monotherapy does not result in a meaningful improvement in clinical outcomes among patients with recurrent ACC.
BACKGROUND:Adenoid cystic carcinomas (ACCs) are malignant salivary gland tumors noteworthy for high rates of late failure with limited salvage therapy options. We have previously shown increased Akt signaling is common in ACC and the human immunodeficiency virus (HIV) protease inhibitor nelfinavir (NFV) inhibits in vitro tumor growth by suppressing Akt signaling. This phase II trial was conducted to determine progression-free survival in response to NFV in patients with recurrent/endstage ACC who have failed standard therapies. METHODS: Eligible patients had recurrent or end-stage ACC and measureable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. NFV was provided at 1250 mg twice daily. RESULTS: Among 15 trial participants, median progression-free survival was 5.5 months (lower 95% bound 4.4 months). No patient achieved a RECIST partial or complete response to therapy. CONCLUSION:NFV monotherapy does not result in a meaningful improvement in clinical outcomes among patients with recurrent ACC.
Authors: Min Guan; Kristen Fousek; Chunling Jiang; Song Guo; Tim Synold; Bixin Xi; Chu-Chih Shih; Warren A Chow Journal: Clin Cancer Res Date: 2011-02-25 Impact factor: 12.531
Authors: Filip Janku; Apostolia M Tsimberidou; Ignacio Garrido-Laguna; Xuemei Wang; Rajyalakshmi Luthra; David S Hong; Aung Naing; Gerald S Falchook; John W Moroney; Sarina A Piha-Paul; Jennifer J Wheler; Stacy L Moulder; Siqing Fu; Razelle Kurzrock Journal: Mol Cancer Ther Date: 2011-01-07 Impact factor: 6.261
Authors: Joseph C Gathe; Robin Wood; Ian Sanne; Edwin DeJesus; Dirk Schürmann; Andrzej Gladysz; Cindy Garris; Naomi Givens; Robert Elston; Jane Yeo Journal: Clin Ther Date: 2006-05 Impact factor: 3.393
Authors: Thomas B Brunner; Matthias Geiger; Gerhard G Grabenbauer; Marga Lang-Welzenbach; Tine S Mantoni; Alexander Cavallaro; Rolf Sauer; Werner Hohenberger; W Gillies McKenna Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544
Authors: Anjali K Gupta; John H Lee; Werner W Wilke; Harry Quon; Gareth Smith; Amit Maity; John M Buatti; Douglas R Spitz Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-01 Impact factor: 7.038
Authors: Anjali K Gupta; Werner W Wilke; Erin N Taylor; Kellie L Bodeker; Henry T Hoffman; Mohammed M Milhem; John M Buatti; Robert A Robinson Journal: Cancer Biol Ther Date: 2009-10-22 Impact factor: 4.742
Authors: Barbara Marengo; Mariapaola Nitti; Anna Lisa Furfaro; Renata Colla; Chiara De Ciucis; Umberto Maria Marinari; Maria Adelaide Pronzato; Nicola Traverso; Cinzia Domenicotti Journal: Oxid Med Cell Longev Date: 2016-06-21 Impact factor: 6.543
Authors: Young Kwang Chae; Su Yun Chung; Andrew A Davis; Benedito A Carneiro; Sunandana Chandra; Jason Kaplan; Aparna Kalyan; Francis J Giles Journal: Oncotarget Date: 2015-11-10
Authors: Patrick M Dillon; Samhita Chakraborty; Christopher A Moskaluk; Prashant J Joshi; Christopher Y Thomas Journal: Head Neck Date: 2015-06-16 Impact factor: 3.147